Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Gene Therapy to Target CD19 for B-cell Malignancies by Alaunos Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Gene Therapy to Target CD19 for B-cell Malignancies is under clinical development by Alaunos Therapeutics and currently in Phase I...
Gene Therapy to Target CD19 for B-cell Malignancies by Alaunos Therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Gene Therapy to Target CD19 for B-cell Malignancies is under clinical development by Alaunos Therapeutics and currently in Phase I...
Gene Therapy to Target CD19 for B-cell Malignancies by Alaunos Therapeutics for Non-Hodgkin Lymphoma: Likelihood of Approval
Gene Therapy to Target CD19 for B-cell Malignancies is under clinical development by Alaunos Therapeutics and currently in Phase I...